ArticleJournal of pediatric gastroenterology and nutrition2026
Liver disease in Shwachman-Diamond syndrome: A comprehensive characterization across the age spectrum.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver disease in Shwachman-Diamond syndrome: A comprehensive characterization across the age spectrum.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesShwachman-Diamond syndrome (SDS) is an inherited bone marrow failure disorder, and its hepatic phenotype is poorly defined. Our objective was to systematically characterize the prevalence, features, and outcomes of liver injury in a multicenter SDS cohort.
methodsRetrospective registry study of 171 patients with biallelic Shwachman-Bodian-Diamond syndrome (SBDS) mutations and evaluable hepatic data. Clinical, laboratory, imaging, elastography, and biopsy findings were extracted from medical records.
resultsChronic hepatitis (CH) was observed in 94 of 171 patients (55%), with a median age at onset of 1.0 year (range 0.04-37.9). At presentation, 71% had alanine aminotransferase (ALT) ≥ 2× upper limit of normal (ULN) (interquartile range [IQR] 81-228.5 U/mL). In contrast, adult-onset CH (n = 5) was characterized by only mild (1-2× ULN) transaminase elevations. CH persisted for a median of 6 years, with resolution in 36% of cases. Hematopoietic stem cell transplantation (HSCT) exposure and liver-related mortality did not differ between patients with and without CH. Ultrasound (226 studies) was the principal imaging modality; 55% of scans in the CH cohort displayed increased echogenicity with preserved size, mirroring no-CH findings. Elastography (n = 41) showed comparable liver stiffness, though controlled attenuation parameter (CAP)-defined steatosis was more common without CH (40% vs. 18%). Biopsies (n = 30) revealed hepatitis (69%) and fibrosis (65%) in pediatric CH, whereas adults showed universal steatosis, often with fibrosis or cirrhosis.
conclusionsLiver disease is common in individuals with SDS. Longitudinal prospective surveillance and mechanistic studies are needed to inform targeted prevention and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.